|
|
![]() Range of Possible Side Effects It is still important to understand your risks. Side effects are a serious matter, but many can be prevented, managed and often reversed by delaying or reducing doses.
Hand-Foot Syndrome Hand-foot syndrome usually occurs on the palms of the hands and soles of the feet. However, it can also occur on other parts of the body where your clothes may be tight or where friction, pressure, rubbing, warmth, and/or sweating occur. You or your caregiver should check regularly for signs of skin irritation and hand-foot syndrome. If you already have peripheral neuropathy (numbness or tingling in the hands and feet) from previous treatment or other conditions, you may not notice the symptoms as easily. Common signs and symptoms of hand-foot syndrome may include:
In most patients, the reaction is mild and improves in one to two weeks without a delay in therapy. However, hand-foot syndrome can become severe in some patients and may require either delaying or stopping therapy. At the first sign of any of these symptoms, please tell your doctor or nurse immediately. They may have specific suggestions to help you reduce the severity of hand-foot syndrome. Because its frequency and severity are usually associated with the chemotherapy dose and/or schedule, hand-foot syndrome may be treated with a delay and/or reduction in therapy until the symptoms are resolved. A delay or reduction in dose typically does not reduce the effectiveness of treatment.
Stomatitis Some common symptoms of stomatitis include:
Hair Loss
Nausea and Vomiting |
|
|
Doxil (doxorubicin HCl), is a prescription medicine that is administered intravenously by your healthcare professional. DOXIL is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy. Please read Important Safety Information below, and talk to your healthcare professional to learn more about DOXIL. Important Safety Information Serious and possibly permanent heart-related side effects that may lead to congestive heart failure can occur in patients treated with DOXIL. Inform your doctor of any history of heart disease, radiation to your chest, or prior chemotherapy. Your doctor may monitor your heart function.Infusion reactions may occur during administration. Be sure to tell your doctor if you have any symptoms during infusion, including: flushing, shortness of breath, facial swelling, headaches, chills, back pain, tightness in your chest or throat, dizziness, or lightheadedness. For most patients, these reactions have resolved within several hours to a day once the infusion is stopped, or for some patients with slowing of the infusion rate. However, in some cases, these reactions may be serious and sometimes life threatening, though they are rarely fatal. DOXIL may severely reduce the number of blood cells (red blood cells, white blood cells, and platelets) in your body. Your doctor may adjust or delay your dose of DOXIL if this occurs. Your doctor may adjust your dose of DOXIL if you have liver problems. You should not take DOXIL if you are nursing. If you are pregnant or are planning to become pregnant, inform your doctor. You should not take DOXIL if you are allergic to doxorubicin HCI or the components of DOXIL. The most common side effects of DOXIL are:
Be sure to tell your doctor immediately if you experience any of these or other symptoms. DOXIL may make the side effects of other anticancer therapies worse when used in combination. Following administration, DOXIL may turn urine and other bodily fluids a reddish-orange color. This is due to the color of DOXIL and will go away as the drug leaves the body. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088). Please click here for full Product Information in PDF format,for more details. |
This site is published by Centocor Ortho Biotech Products, L.P. which is solely responsible for its contents. © Centocor Ortho Biotech Products, L.P. 2003-2010 Last modified on:Dec 03 2009 at 10:48:01 EST |
![]() |




